Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mefloquine→

Mefloquine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
53230-10-7
Molecular formula
C17H16F6N2O
Molecular weight
378.31 g/mol
Drug class
Antimalarial
Mechanism of action
Acts as a blood schizonticide against erythrocytic stages of Plasmodium species. Its precise mechanism of action is not known.
Indications / reported uses
  • Treatment of mild to moderate acute malaria caused by mefloquine-susceptible Plasmodium falciparum or Plasmodium vivax
  • Prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria, including chloroquine-resistant P. falciparum

Sources: DailyMed — Mefloquine hydrochloride prescribing information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mefloquine Environmental Risk Assessment (ERA) (the Mefloquine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.